Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Normative Database for RA Imaging with Tc99m Tilmanocept
NCT04947137Phase 2Completed
- Sponsor
- Navidea Biopharmaceuticals, Inc.
- Start
- May 2021
- Primary completion
- Jan 2022
- Modality
- Radiopharmaceutical, Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of technetium tc 99m tilmanocept in rheumatoid arthritis (RA), sponsored by Navidea Biopharmaceuticals, Inc.. Started May 2021; status: completed.
02
Drugs
technetium tc 99m tilmanocept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04947137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04947137.